The European Commission has approved Merck & Co.’s Keytruda anti-PD-1 therapy for the adjuvant treatment of adults with stage III melanoma and lymph node involvement who have undergone complete resection. This approval is based on data from the pivotal Phase 3 EORTC1325/KEYNOTE-054 trial, conducted in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC).…
Merck Signs Definitive Agreement To Acquire Viralytics For $394M
Merck and Viralytics announce acquisition agreement, expanding Merck’s leading immuno-oncology pipeline. Merck, known as MSD outside the United States and Canada, and Viralytics Limited signed a definitive agreement under which it is proposed that Merck, through a subsidiary, will acquire Viralytics, an Australian publicly traded company focused on oncolytic immunotherapy treatments for a range of cancers…
Merck And AstraZeneca Genetic Disorder Treatment Gets Orphan Drug Status
AstraZeneca and Merck, known as MSD outside the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). NF1 is an incurable genetic condition that affects one in 3,000 births with highly-variable symptoms including…
Merck Discontinues Study For Treatment Of Prodromal Alzheimer’s Disease
Merck announces discontinuation of APECS study evaluating verubecestat (MK-8931) for the treatment of people with prodromal Alzheimer’s disease. Merck, known as MSD outside the United States and Canada, announced Tuesday that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an investigational small molecule inhibitor of…
